IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC).

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Personeni, Nicola;Rimassa, Lorenza;
2022-01-01

Abstract

IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC).
Advanced HCC
Atezolizumab
Bevacizumab
First line
Systemic treatment
Albumins
Antibodies, Monoclonal, Humanized
Bevacizumab
Bilirubin
Female
Humans
Male
Sorafenib
alpha-Fetoproteins
Antineoplastic Agents
Carcinoma, Hepatocellular
Liver Neoplasms
Venous Thrombosis
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/69947
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact